Research ArticleArticle
Open Access
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale
Laure Gossec, Vibeke Strand, Clare Proudfoot, Chieh-I Chen, Sophie Guillonneau, Toshio Kimura, Hubert van Hoogstraten, Erin Mangan and Matthew Reaney
The Journal of Rheumatology March 2019, jrheum.180904; DOI: https://doi.org/10.3899/jrheum.180904
Laure Gossec
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Vibeke Strand
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Clare Proudfoot
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Chieh-I Chen
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Sophie Guillonneau
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Toshio Kimura
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Hubert van Hoogstraten
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Erin Mangan
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Matthew Reaney
From the Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France; Stanford University, Palo Alto, California, USA; Sanofi, Guildford, UK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA; Sanofi, Paris, France; Sanofi, Bridgewater, New Jersey, USA. Supported by Sanofi and Regeneron Pharmaceuticals Inc., which developed sarilumab. L. Gossec has acted as a consultant for Sanofi. V. Strand has acted as a consultant for Regeneron Pharmaceuticals Inc. and Sanofi. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of Novartis. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau and H. van Hoogstraten are employees of and hold shares or options in Sanofi. L. Gossec, MD, PhD, Sorbonne Université and Rheumatology Department, Hôpital Pitié Salpêtrière, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS); V. Strand, MD, Stanford University; C. Proudfoot, PhD, Novartis; C.I. Chen, MPH, Regeneron Pharmaceuticals Inc.; S. Guillonneau, MSc, Sanofi; T. Kimura, MSc, Regeneron Pharmaceuticals Inc.; H. van Hoogstraten, MD/PhD, Sanofi; E. Mangan, PhD, Regeneron Pharmaceuticals Inc.; M. Reaney, MSc, formerly of Sanofi. Address correspondence to M. Reaney, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. E-mail: matthew.reaney@iqvia.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication February 6, 2019.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale
Laure Gossec, Vibeke Strand, Clare Proudfoot, Chieh-I Chen, Sophie Guillonneau, Toshio Kimura, Hubert van Hoogstraten, Erin Mangan, Matthew Reaney
The Journal of Rheumatology Mar 2019, jrheum.180904; DOI: 10.3899/jrheum.180904
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale
Laure Gossec, Vibeke Strand, Clare Proudfoot, Chieh-I Chen, Sophie Guillonneau, Toshio Kimura, Hubert van Hoogstraten, Erin Mangan, Matthew Reaney
The Journal of Rheumatology Mar 2019, jrheum.180904; DOI: 10.3899/jrheum.180904